Episode Summary
Join us for a conversation with internationally recognized Medical Oncologists and researchers, Prof Ben Solomon & A/Prof Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.
Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.
Show Hosts
This episode’s host are:
- Prof Ben Solomon, Scientific Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer
- A/Prof Thomas John, Scientific Committee Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer Centre